| --- | --- | |------------------------------------------------------|-------| | | | | | | | | | | | | | | | | Powerful Science Meaningful Medicines Changing Lives | | | Nasdaq: ETNB | | | March 2021 | | Disclaimer 1 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements o ...

Financial Performance - The company reported a net loss of $14.6 million for the three months ended September 30, 2020, compared to a net loss of $18.7 million for the same period in 2019, representing a decrease of $4.1 million [96]. - Total operating expenses for Q3 2020 were $14.4 million, up from $8.2 million in Q3 2019, indicating an increase of $6.2 million [96]. - Total operating expenses for the nine months ended September 30, 2020, were $36.8 million, an increase of $19.8 million, or 116%, from $17.0 million for the same period in 2019 [101]. - Net cash used in operating activities was $32.2 million for the nine months ended September 30, 2020, compared to $14.3 million for the same period in 2019 [117]. - Other expenses, net decreased by $10.3 million to $0.2 million for the three months ended September 30, 2020, from $10.5 million in the prior year [99]. Research and Development - Research and development expenses increased to $11.2 million in Q3 2020 from $6.7 million in Q3 2019, reflecting an increase of $4.5 million [96]. - The company expects research and development expenses to increase substantially as it continues to invest in the development of BIO89-100 and future product candidates [91]. - Research and development expenses increased by $4.5 million, or 68%, to $11.2 million for the three months ended September 30, 2020, compared to $6.7 million for the same period in 2019 [97]. - Research and development expenses for the nine months ended September 30, 2020, increased by $13.3 million, or 94%, to $27.4 million from $14.2 million in the prior year [102]. - The company successfully completed a Phase 1b/2a clinical trial for BIO89-100, showing a relative reduction in liver fat of up to 60% versus baseline and up to 70% versus placebo [76]. - A Phase 2b trial for NASH patients is planned to be initiated in the first half of 2021, alongside a new paired-biopsy histology cohort [77]. - The ongoing COVID-19 pandemic may disrupt clinical trials and impact development timelines, including the Phase 2 trial in SHTG patients [86]. - The company plans to increase research and development expenses substantially for the foreseeable future as it continues clinical development [110]. Financial Position - As of September 30, 2020, the company had cash, cash equivalents, and short-term investments totaling $219.2 million, expected to meet cash requirements through Q2 2023 [84]. - The company has an accumulated deficit of $110.5 million as of September 30, 2020, and anticipates continued significant expenses as it advances BIO89-100 through clinical trials [85]. - The company had available cash and cash equivalents of $219.2 million as of September 30, 2020, with an accumulated deficit of $110.5 million [106]. - The company expects existing cash and short-term investments to fund operations through the second quarter of 2023 [111]. - Net cash provided by financing activities was $158.2 million for the nine months ended September 30, 2020, primarily from public offerings of common stock [122]. Accounting and Compliance - The company has not entered into any off-balance sheet arrangements and does not hold any interests in variable interest entities [125]. - There have been no significant changes in critical accounting policies and estimates compared to the previous annual report, except as noted in the condensed consolidated financial statements [126]. - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to delay adopting new or revised accounting standards until they apply to private companies [127]. - The extended transition period under the JOBS Act may result in the company's financial statements being less comparable to those of companies that comply with new accounting pronouncements [128]. Administrative Expenses - General and administrative expenses rose by $1.7 million, or 112%, to $3.2 million for the three months ended September 30, 2020, from $1.5 million in the prior year [98].

| --- | --- | --- | --- | |------------------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Developing a Differentiated | | | | | FGF21 for Non-Alcoholic Steatohepatitis (NASH) and Severe Hypertriglyceridemia (SHTG) | | | | | Nasdaq: ETNB | | | | | August 2020 | | | | Disclaimer 1 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities law ...

Financial Performance - The company reported a net loss of $11.8 million for the three months ended June 30, 2020, compared to a net loss of $15.0 million for the same period in 2019, representing a decrease of $3.2 million [99]. - The net loss for the six months ended June 30, 2020, was $22.3 million, compared to a net loss of $19.4 million for the same period in 2019, representing an increase in loss of $2.9 million [104]. - Net cash used in operating activities for the six months ended June 30, 2020, was $19.3 million, compared to $8.1 million for the same period in 2019 [119]. - The company has an accumulated deficit of $95.9 million as of June 30, 2020, and expects to continue incurring significant expenses as it advances its product candidates [86]. Research and Development - Research and development expenses increased by $5.3 million, or 167%, to $8.4 million for the three months ended June 30, 2020, from $3.1 million for the same period in 2019 [100]. - Research and development expenses rose by $8.7 million, or 117%, to $16.2 million for the six months ended June 30, 2020, compared to $7.5 million for the same period in 2019 [105]. - The company plans to increase research and development expenses significantly for the foreseeable future as it continues clinical development [112]. - The company expects to report topline data from its Phase 1b/2a clinical trial in NASH patients in late Q3 to early Q4 2020 [79]. - The company plans to initiate a Phase 2 trial in patients with severe hypertriglyceridemia (SHTG) in Q3 2020, pending a conducive environment due to COVID-19 [80]. - The ongoing COVID-19 pandemic has caused disruptions to clinical trials, including the enrollment of 81 patients in the Phase 1b/2a trial, which is 98% of the target [88]. Cash and Funding - As of June 30, 2020, the company had cash, cash equivalents, and short-term investments totaling $73.9 million, which, along with net proceeds from a July 2020 offering, is expected to meet cash requirements through the second quarter of 2022 [84]. - The company raised approximately $78.3 million in net proceeds from a public offering completed on July 10, 2020 [83]. - The company completed a public offering of 3,047,040 shares at a price of $27.50 per share, receiving gross proceeds of $83.8 million [111]. - The company anticipates that existing cash and net proceeds from the July 2020 offering will be sufficient to fund operations through the second quarter of 2022 [113]. Operating Expenses - The company incurred total operating expenses of $11.7 million for the three months ended June 30, 2020, compared to $4.0 million for the same period in 2019, an increase of $7.7 million [99]. - General and administrative expenses increased by $4.8 million, or 354%, to $6.2 million for the six months ended June 30, 2020, from $1.4 million for the same period in 2019 [106]. - The company expects to continue generating substantial operating losses as it expands research and development activities [116]. - Other expenses (income), net decreased by $10.6 million to $(59,000) for the six months ended June 30, 2020, from $10.5 million for the same period in 2019 [107].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to ____________ Commission File Number: 001-39122 89bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39122 89bio, Inc. (Exact name of Registrant as specified in its Charter) Delaware 36-4946844 incorporation or organization)(I.R.S. Em ...

| --- | --- | --- | |-------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | Developing a Differentiated FGF21 for NASH and SHTG | | | | | | | | February 2020 | | | | www.89bio.com | | | Disclaimer 1 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and as ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to ____________ Commission File Number: 001-39122 89bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4946844 (Sta ...